This week, I'm looking for the fourth healthcare representative of six for my Ivy portfolio.

That healthcare sector includes ten industries all related to testing, diagnosing and treating what ails us: biotechnology; diagnostics & research; drug manufacturers - major and - specialty & generic; healthcare plans; long-term care facilities; medical care; medical devices; medical distribution; medical supplies.

Today I'm reviewing a large-cap medical devices company named Stryker Corporation. Its trading ticker symbol is SYK.

Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices.

The product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, and spinal devices.

Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment.

Approximately 35% of Stryker's total revenue currently comes from outside the United States.

The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 80 countries.

Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

I use three key data points to gauge the value of any dividend equity-like Stryker Corporation:

(1) Price

(2) Dividends

(3) Returns

Besides those three, several other keys will finally unlock an equity or fund in which to invest.

Those first three primary keys, however, best tell whether a company has made, is making, and will make money.

SYK Price

Stryker's price per share closed at $192.67 Friday. A year ago its price was $162.06. Price rose $30.61 or 19% in the past year.

Assuming Stryker's stock trades in the range of $160 to $220 this year, Stryker's recent $192.67 price could rise by $3.33 and go to $196.00 by early-April, 2020.

SYK Dividends

Stryker's most recent Quarterly dividend was $0.52 declared February 6th and payable, April 30th.

That $0.52 Q dividend equates to an annual payout of $2.08 for a yield of 1.08% at yesterday's $192.67 closing price.

Gains For SYK?

Adding the $2.08 annual estimated dividend to my $3.33 estimate of Stryker's price upside shows a $5.41 potential gross annual gain, per share, which will be reduced by costs to trade those shares.

Say we put a little under $1,000.00 today at the $192.67 recent stock price would buy us 5 Stryker Corporation shares.

A $10 broker fee paid half at purchase and half at sale costs $2.00 per share.

Subtract that $2.00 brokerage cost from the estimated $5.41 gross annual gain leaves a net gain of $3.41 X 5 shares

= $17.05 or a 1.77% net gain on a $963.35 investment.

Therefore, Stryker Corporation, whose trading ticker symbol is SYK, now shows a possible net gain of nearly 1.77% including a 1.08% dividend yield.

Thirty-two brokers cover this stock:

Fifteen say 'buy" SYK.

Seven say SYK will "outperform".

Nine say "hold" SYK.

One says SYK will "underperform".

Therefore, you can look at  Stryker Corporation and see it has made money, is making money, and could net 1.77% gains including a 1.08% dividend yield. It could be more, it could be less.

The above speculation is based on past year performance. The actual results remain to be seen to determine if Stryker Corporation is worth your time and money.